ArticleJournal of global infectious diseases
Isolation of a Novel Phage and Targeting Biofilms of Drug-Resistant Oral Enterococci.
Article in Journal of global infectious diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Phage therapy as an alternative strategy for oral bacterial infections: a systematic review.BMC oral health · 2025Pooled it
- Bacteriophage research in India and its implications for human health: A scoping review.The Indian journal of medical research · 2026Article
- Recent perspectives on precision-targeting therapy against oral biofilm.Journal of oral microbiology · 2026Review
- Microbiota-based therapies in oral health and disorders.Folia microbiologica · 2025Review
- Fully Characterized Effective Bacteriophages Specific against Antibiotic-ResistantMedicina (Kaunas, Lithuania) · 2024Article
- Molecular Aspects of the Functioning of Pathogenic Bacteria Biofilm Based onInternational journal of molecular sciences · 2024Review
- SVep1, a temperate phage of human oral commensalFrontiers in microbiology · 2023Article
- Targeted Anti-Biofilm Therapy: Dissecting Targets in the Biofilm Life Cycle.Pharmaceuticals (Basel, Switzerland) · 2022Review
- What Are the Potential Benefits of Using Bacteriophages in Periodontal Therapy?Antibiotics (Basel, Switzerland) · 2022Review
- Association of CRISPR-Cas System with the Antibiotic Resistance and Virulence Genes in Nosocomial Isolates ofInfection and drug resistance · 2022Article
- Isolation and characterization of bacteriophages from wastewater sources onIranian journal of microbiology · 2021Article
- Characterization of the Bacteriophage vB_EfaS-271 InfectingInternational journal of molecular sciences · 2020Article
- Genome Analysis of theAvicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEnterococci are now recognized as the second most cause of nosocomial infections worldwide. The emergence of multidrug-resistant strains in the organism has given rise to alternative strategies such as phage therapy. In this study, an MATERIALS AND
methodsBacteriophage against
resultsTEM microscopy showed that the phage belonged to Siphoviridae family. In the presence of the novel phage, the metabolic activity of enterococci biofilm was reduced at 48 h of contact. A difference of at least 5 log CFU/ml was seen in the live cells of the control biofilm, and the phage treated biofilm of enterococci isolates.
conclusionThe study shows that the novel phage inhibits biofilm production in oral enterococci isolates from periodontitis patients but has a narrow host range. The role of bacteriophages as strong biotechnological and natural therapeutic agents for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.